目的:观察扶正固本方联合放疗治疗恶性肿瘤骨转移疼痛的临床疗效。方法:将50例恶性肿瘤骨转移痛患者采用随机数字表法随机分为治疗组和对照组各25例。对照组给予局部放疗治疗,治疗组在对照组治疗基础上给予中药汤剂扶正固本方(黄芩、淫...目的:观察扶正固本方联合放疗治疗恶性肿瘤骨转移疼痛的临床疗效。方法:将50例恶性肿瘤骨转移痛患者采用随机数字表法随机分为治疗组和对照组各25例。对照组给予局部放疗治疗,治疗组在对照组治疗基础上给予中药汤剂扶正固本方(黄芩、淫羊藿、女贞子、何首乌、熟地黄、茜草、黄精、人参)治疗,1 d 1剂,煎3次,分3次温服。两组均以7 d为1个疗程,共治疗2个疗程。结果:治疗组完全缓解2例,部分缓解19例,稳定3例,进展1例,有效率为84.0%;对照组完全缓解0例,部分缓解14例,稳定7例,进展4例,有效率为56.0%。两组对比,差别有统计学意义(P<0.05)。结论:扶正固本方联合放疗治疗恶性肿瘤骨转移疼痛具有良好的临床疗效,能够缓解症状、减轻不良反应。展开更多
Objective:To evaluate the efficacy and safety of zoledronic acid for the pain caused by metastatic tumor of bone.Methods:52 patients with metastatic tumor of bone were randomly divided into two groups.The zoledronic a...Objective:To evaluate the efficacy and safety of zoledronic acid for the pain caused by metastatic tumor of bone.Methods:52 patients with metastatic tumor of bone were randomly divided into two groups.The zoledronic acid group received 4 mg zoledronic acid infusion for 30 minutes and the control group received 90 mg pamidronate infusion for 6 hours. Results:The effective rates in zoledronic acid group and control group were 73.08%and 69.23%respectively.No significant difference was observed between the two groups.The median pain relief onset at days 5 and 7,respectively,and no significant difference was observed.The ECOG scores on the 7th day after medication:the differences in the zoledronic acid group before and after medication and between the two groups were both significant(P<0.001 and P=0.0448).The adverse reac- tion was no significant difference between the two groups.Conclusion:Zoledronic acid is efficient and safe in the treatment of pain caused by metastatic tumor of bone and it has low adverse reaction rate and convenient shorter using time.展开更多
文摘目的:观察扶正固本方联合放疗治疗恶性肿瘤骨转移疼痛的临床疗效。方法:将50例恶性肿瘤骨转移痛患者采用随机数字表法随机分为治疗组和对照组各25例。对照组给予局部放疗治疗,治疗组在对照组治疗基础上给予中药汤剂扶正固本方(黄芩、淫羊藿、女贞子、何首乌、熟地黄、茜草、黄精、人参)治疗,1 d 1剂,煎3次,分3次温服。两组均以7 d为1个疗程,共治疗2个疗程。结果:治疗组完全缓解2例,部分缓解19例,稳定3例,进展1例,有效率为84.0%;对照组完全缓解0例,部分缓解14例,稳定7例,进展4例,有效率为56.0%。两组对比,差别有统计学意义(P<0.05)。结论:扶正固本方联合放疗治疗恶性肿瘤骨转移疼痛具有良好的临床疗效,能够缓解症状、减轻不良反应。
文摘Objective:To evaluate the efficacy and safety of zoledronic acid for the pain caused by metastatic tumor of bone.Methods:52 patients with metastatic tumor of bone were randomly divided into two groups.The zoledronic acid group received 4 mg zoledronic acid infusion for 30 minutes and the control group received 90 mg pamidronate infusion for 6 hours. Results:The effective rates in zoledronic acid group and control group were 73.08%and 69.23%respectively.No significant difference was observed between the two groups.The median pain relief onset at days 5 and 7,respectively,and no significant difference was observed.The ECOG scores on the 7th day after medication:the differences in the zoledronic acid group before and after medication and between the two groups were both significant(P<0.001 and P=0.0448).The adverse reac- tion was no significant difference between the two groups.Conclusion:Zoledronic acid is efficient and safe in the treatment of pain caused by metastatic tumor of bone and it has low adverse reaction rate and convenient shorter using time.
